NCT01591551View on ClinicalTrials.gov

NAPS-MS: NAtalizumab Effects on Parameters of Sleep in Patients With Multiple Sclerosis Experiencing Fatigue or Sleepiness

PHASE4CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

Natalizumab (Tysabri)

300 mg IV every 4 weeks

Trial Locations (3)

11772

South Shore Neurologic Associates, Patchogue

27262

Cornerstone Neurology, High Point

97225

Providence Brain Institute, Portland

Sponsors

Collaborators (1)

Biogen
All Listed Sponsors
collaborator

Biogen

INDUSTRY

lead

Cornerstone Health Care, PA

OTHER